A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage
- Posted on April 9, 2026
- By CNBC
- 0 Views
A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
